- Daiichi eyes almost $15B in oncology sales by 2030 in ADC franchise pushDaiichi Sankyo is betting on its oncology franchise to push it past 3 trillion Japanese yen ($19 billion) in 2030 revenues. The drugmaker published a new five-year business plan on Monday ...Endpoints · 2mo ago↗ source
- New home for Novo's Parkinson's cell therapy; GSK's deal to sell drug in ChinaPlus, label expansions for two drugs targeting rare diseases, and Genmab scraps a Phase 1 cancer trial: 🧠 Novo's Parkinson's cell therapy finds a biotech home: Novo Nordisk has found a home for…Endpoints · 2mo ago↗ source
- Inhibrx says combo therapy shrank more tumors than Merck's Keytruda aloneSan Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer. The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank more…